Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Founded in 1987, Merit Medical set out to build the worldâs most customer-focuse...
Founded in 1987, Merit Medical set out to build...
Utah Medical Products IncÂŽ, established in 1978, develops, manufactures and marke...
Utah Medical Products IncÂŽ, established in 197...
We are a clinical-stage biopharmaceutical company focused on the development of no...
We are a clinical-stage biopharmaceutical compa...
Alterola Biotech Inc. provides medicinal delivery systems, offering nutraceutrical...
Alterola Biotech Inc. provides medicinal delive...
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...
Astellas Pharma Inc. is a pharmaceutical compan...
Genetic Technologies is a leader in the development of genetic technology. Our tes...
Genetic Technologies is a leader in the develop...
Heat Biologics a biopharmaceutical company that develops immunotherapies with the ...
Heat Biologics a biopharmaceutical company that...
Join the National Investor Network and get the latest information with your interests in mind.